H. Roschitzki-Voser

发表

Design, construction, and characterization of a second‐generation DARPin library with reduced hydrophobicity

M. Grütter, M. Seeger, Reto Zbinden, 2013, Protein science : a publication of the Protein Society.

A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.

U. Dafni, R. Stahel, S. Peters, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Human caspases in vitro: expression, purification and kinetic characterization.

M. Grütter, P. Mittl, A. Baici, 2012, Protein expression and purification.

Temperature-mediated microhabitat choice and development time based on the pgm locus in the yellow dung fly Scathophaga stercoraria

W. Blanckenhorn, H. Roschitzki-Voser, Y. Choffat, 2012 .

Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial.

U. Dafni, R. Stahel, S. Peters, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial

N. Reinmuth, U. Dafni, R. Stahel, 2020 .

Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis

U. Dafni, R. Stahel, R. Rosell, 2022, ESMO open.

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.

U. Dafni, D. de Ruysscher, D. Ruysscher, 2019, Lung cancer.

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.

U. Dafni, R. Stahel, C. Britschgi, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Progression-free and overall survival for concurrent nivolumab with standard concurrent chemo-radiotherapy in locally advanced stage IIIA/B NSCLC: Results from the European Thoracic Oncology Platform NICOLAS phase II trial (ETOP 6-14).

U. Dafni, D. de Ruysscher, R. Stahel, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.

U. Dafni, R. Stahel, A. Addeo, 2022, Lung cancer.

A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

R. Stahel, H. Roschitzki-Voser, E. Nadal, 2019, Annals of Oncology.

Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial.

U. Dafni, R. Stahel, S. Peters, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).

U. Dafni, E. Smit, R. Stahel, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Selective and sensitive monitoring of caspase-1 activity by a novel bioluminescent activity-based probe.

M. Grütter, P. Mittl, H. Roschitzki-Voser, 2010, Chemistry & biology.

Altering lamina assembly reveals lamina-dependent and -independent functions for A-type lamins

O. Medalia, J. Lammerding, M. Grütter, 2015, Journal of Cell Science.

Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism.

Andreas Plückthun, Guido Capitani, Markus G Grütter, 2007, Structure.

Consolidation nivolumab and ipilimumab versus observation in limited-disease small cell lung cancer after chemo-radiotherapy - Results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.

K. Nackaerts, U. Dafni, D. de Ruysscher, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

The crystal structure of human pyrin b30.2 domain: implications for mutations associated with familial Mediterranean fever.

M. Grütter, P. Mittl, H. Roschitzki-Voser, 2009, Journal of molecular biology.

VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial

R. Stahel, B. Cho, M. Provencio, 2021, Annals of Oncology.

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.

U. Dafni, D. Ruysscher, R. Stahel, 2018 .

Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials.

U. Dafni, R. Stahel, M. Guillot, 2021, Lung cancer.

LBA84 Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial

K. Nackaerts, U. Dafni, D. Ruysscher, 2020 .

A randomised open-label phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC - the ETOP and EORTC SPLENDOUR trial.

N. Reinmuth, U. Dafni, R. Stahel, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial.

U. Dafni, E. Smit, A. Dingemans, 2022, Lung cancer.

A single-arm phase II trial of afatinib in pretreated patients with advanced NSCLC harboring a HER2 mutation: The ETOP NICHE trial.

U. Dafni, E. Smit, R. Stahel, 2017 .

Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial

U. Dafni, D. Ruysscher, R. Stahel, 2019, Annals of Oncology.

A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial.

N. Reinmuth, U. Dafni, R. Stahel, 2018, Annals of Oncology.

Design, construction, and characterization of a second‐generation DARPin library with reduced hydrophobicity

M. Grütter, M. Seeger, Reto Zbinden, 2013, Protein science : a publication of the Protein Society.